Anne  Lesage net worth and biography

Anne Lesage Biography and Net Worth

Chief Early Development Officer of Pharvaris

Dr. Anne Lesage is Chief Early Development Officer at Pharvaris.  Dr. Lesage is a co-founder of Pharvaris and has led the translational science, preclinical and non-clinical development since its inception. Dr. Lesage has over 30 years’ experience in drug discovery, preclinical, and early development.

From 1992 until 2010, Dr. Lesage held different leadership positions with increasing responsibility in the neuroscience drug discovery unit at Johnson & Johnson. By 2005, Dr. Lesage served as the biology head of psychiatry.

Dr. Lesage is an inventor on 10 patents and an author of 46 publications. Dr. Lesage founded GrayMatters Consulting in 2010 and advises early and late-stage biotech companies, venture capital organizations, and government agencies and initiatives. In 2013, Dr. Lesage co-founded Kosa Pharma.

Dr. Lesage is trained as a biochemist and holds a Ph.D. in molecular biology. Dr. Lesage studied biochemistry at the University of Ghent, received her Ph.D. in the group of Professor Walter Fiers, and was a post-doctoral fellow in the Child Psychiatry department of Stanford University Medical School and in the CNRS Laboratory of Viral Oncology of Hospital Paul Brousse in Paris.

What is Anne Lesage's net worth?

The estimated net worth of Anne Lesage is at least $1.62 million as of April 22nd, 2026. Dr. Lesage owns 56,450 shares of Pharvaris stock worth more than $1,616,164 as of April 27th. This net worth evaluation does not reflect any other assets that Dr. Lesage may own. Learn More about Anne Lesage's net worth.

How do I contact Anne Lesage?

The corporate mailing address for Dr. Lesage and other Pharvaris executives is , , . Pharvaris can also be reached via phone at 31-71-203-6410 and via email at [email protected]. Learn More on Anne Lesage's contact information.

Has Anne Lesage been buying or selling shares of Pharvaris?

During the past quarter, Anne Lesage has sold $438,728.00 of Pharvaris stock. Most recently, Anne Lesage sold 100 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $30.03, for a transaction totalling $3,003.00. Following the completion of the sale, the insider now directly owns 56,450 shares of the company's stock, valued at $1,695,193.50. Learn More on Anne Lesage's trading history.

Who are Pharvaris' active insiders?

Pharvaris' insider roster includes Anne Lesage (Chief Early Development Officer), and Berndt Modig (Chief Executive Officer, Director (CH)). Learn More on Pharvaris' active insiders.

Are insiders buying or selling shares of Pharvaris?

In the last twelve months, insiders at the sold shares 9 times. They sold a total of 54,426 shares worth more than $1,578,272.67. The most recent insider tranaction occured on April, 23rd when insider Peng Lu sold 100 shares worth more than $3,003.00. Learn More about insider trades at Pharvaris.

Information on this page was last updated on 4/23/2026.

Anne Lesage Insider Trading History at Pharvaris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2026Sell100$30.03$3,003.0056,450View SEC Filing Icon  
4/22/2026Sell7,500$30.05$225,375.0056,450View SEC Filing Icon  
4/22/2026Sell7,000$30.05$210,350.00156,969View SEC Filing Icon  
See Full Table

Anne Lesage Buying and Selling Activity at Pharvaris

This chart shows Anne Lesage's buying and selling at Pharvaris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharvaris Company Overview

Pharvaris logo
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $28.92
Low: $28.36
High: $29.72

50 Day Range

MA: $27.43
Low: $25.34
High: $30.04

2 Week Range

Now: $28.92
Low: $14.59
High: $30.24

Volume

20,745 shs

Average Volume

170,617 shs

Market Capitalization

$1.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A